Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Complete title: AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway –Mutant Acute Lymphoblastic Leukmia

Research Study Number AALL1521
 
Principal Investigator Colleen Annesley, MD
 
Phase II

Research Study Description

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number AALL1521
 
Contact Colleen Annesley, MD
 
Telephone 206/987-2106
 
E-mail
 

Keywords: Lymphoma, Burkitt; Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Virus Diseases; Lymphoma, B-Cell; Leukemia, B-Cell, Lymphoblastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Epstein-Barr Virus Infections; Herpesviridae Infections; Immune System Diseases; DNA Virus Infections; Tumor Virus Infections

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials